Ovid Therapeutics Inc.OVID
| Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net loss | -64,806,054 | -51,979,610 | -60,461,243 | -81,035,576 | 123 | -54,169,029 | -52,338,959 | -26 |
|---|
| Change in fair value of royalty monetization liability | - | - | - | - | - | - | - | -30 |
|---|
| Unrealized (gain) loss on equity investments | - | - | - | - | - | -454,811 | 2 | 3 |
|---|
| Change In Accrued Interest And Accretion Of Discounts Short Term Investments | - | - | - | - | - | - | -2,172,254 | -3 |
|---|
| Stock-based compensation expense | 6 | 7 | 5 | 8 | 5 | 7 | 7 | 6 |
|---|
| Depreciation and amortization expense | 80,310 | 141,733 | 255,002 | 306,848 | 237,079 | 512,505 | 568,282 | 1 |
|---|
| Noncash operating lease expense | - | - | - | - | - | 869,100 | 1 | 1 |
|---|
| Change in lease liability | - | - | - | - | - | - | -533,946 | -1 |
|---|
| Prepaid expenses and other current assets | 793,258 | 1 | -224,458 | 724,575 | -14,089 | -109,292 | 1 | -1 |
|---|
| Accounts payable | 1 | 2 | -653,953 | 2 | 2 | -5,174,136 | 2 | -1 |
|---|
| Accrued expenses | 1 | 1 | 2 | 5 | -4,361,410 | -3,166,606 | 2 | -1 |
|---|
| Net cash used in operating activities | - | -45,558,480 | -51,090,622 | -51,583,914 | 119 | -55 | -46 | -56 |
|---|
| Purchase of marketable securities | - | 50 | 35 | 10 | - | 173 | 112 | 73 |
|---|
| Sales/maturities of marketable securities | - | - | - | - | - | 90 | 120 | 128 |
|---|
| Purchase of long-term equity investment | - | - | - | - | - | 3 | 10 | - |
|---|
| Purchases of property and equipment | 38,907 | 33,871 | 57,156 | 127,240 | 184,008 | 1 | 40,308 | 0 |
|---|
| Software development and other costs | - | - | 186,889 | 263,440 | 5,400 | 194,397 | 97,147 | 0 |
|---|
| Net cash provided by (used in) investing activities | - | -5,363,642 | -30,041,049 | 35 | -1,821,400 | -87,883,217 | -2,580,605 | 55 |
|---|
| Proceeds from Stock Options Exercised | 27,043 | 111,378 | - | 300,821 | 807,191 | 180,658 | 535,201 | 1 |
|---|
| Proceeds from royalty monetization agreement | - | - | - | - | - | - | 30 | - |
|---|
| Net cash provided by financing activities | - | 286,140 | 87 | 47 | 904,082 | 180,658 | 31 | 1 |
|---|
| Net decrease in cash, cash equivalents and restricted cash | - | - | - | - | - | - | -17,826,329 | -1 |
|---|